{
    "id": 2746,
    "fullName": "BID dec exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "BID dec exp indicates decreased expression of the Bid protein. However, the mechanism causing the decreased expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 637,
        "geneSymbol": "BID",
        "terms": [
            "BID",
            "FP497"
        ]
    },
    "variant": "dec exp",
    "createDate": "12/12/2014",
    "updateDate": "07/06/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1459,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a preclinical study, the protein-transduction domain TAT fused to BID delivered BID to cancer cell lines and sensitized NSCLC cells to TNF-related apoptosis-inducing ligand (TRAIL) or camptothecin (PMID: 25326334).",
            "molecularProfile": {
                "id": 2561,
                "profileName": "BID dec exp"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1326,
                    "pubMedId": 25326334,
                    "title": "Controlled delivery of BID protein fused with TAT peptide sensitizes cancer cells to apoptosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25326334"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1458,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a preclinical study, the protein-transduction domain TAT fused to BID delivered BID to cancer cell lines and sensitized prostrate cancer cells to TNF-related apoptosis-inducing ligand (TRAIL) or camptothecin (PMID: 25326334).",
            "molecularProfile": {
                "id": 2561,
                "profileName": "BID dec exp"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1326,
                    "pubMedId": 25326334,
                    "title": "Controlled delivery of BID protein fused with TAT peptide sensitizes cancer cells to apoptosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25326334"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2561,
            "profileName": "BID dec exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}